Potential impact of accelerating the primary dose of pneumococcal conjugate vaccine in infants

Archives of Pediatrics and Adolescent Medicine

Volumn 163, Issue 5, 2009, Pages 422-425

  Stancil, Jennifer M ^a   Peters, Timothy R ^a   Givner, Laurence B ^a   Poehling, Katherine A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; GEOGRAPHIC DISTRIBUTION; HUMAN; INFANT; MAJOR CLINICAL STUDY; PNEUMOCOCCAL INFECTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; STATISTICAL ANALYSIS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINATION;

AGE FACTORS; COHORT STUDIES; HUMANS; INFANT; MODELS, THEORETICAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES;

EID: 66149146594     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpediatrics.2009.39     Document Type: Article

References (35)

1. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297(16):1784-1792.
2. Tan TQ, Mason EO Jr, Wald ER, et al. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics. 2002;110 (1 Pt 1):1-6.
3. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113 (3 pt 1):443-449.
4. Gonzalez BE, Hulten KG, Lamberth L, Kaplan SL, Mason EO Jr; the US Pediatric Multicenter Pneumococcal Surveillance Group. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis J. 2006;25(4):301-305.
5. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196 (9):1346-1354.
6. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46(2):174-182.
7. Bender JM, Ampofo K, Korgenski K, et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis. 2008;46(9):1346-1352.
8. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR Morb Mortal Wkly Rep. 2008;57(6):144-148.
9. Advisory Committee on Immunization Practices. Preventing pneumococcal disease amonginfants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-9):1-35.
10. Szilagyi PG, Griffin MR, Shone LP, et al; New Vaccine Surveillance Network. The impact of conjugate pneumococcal vaccination on routine childhood vaccination and primary care use in 2 counties. Pediatrics. 2006;118(4):1394- 1402.
11. Centers for Disease Control and Prevention Web site. Estimated vaccination coverage with individual vaccines by 3 months of age by state and local area US, National Immunization Survey, July 2006 - June 2007. http://www2a.cdc.gov/nip/coverage/nis/nis-iap.asp?fmt=v&rpt= tab04-3mo-iap&qtr=Q3/2006-Q2/2007. Accessed August 19, 2008.
12. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295(14):1668-1674.
13. Whitney CG, Farley MM, Hadler J, et al; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-1746.
14. Talbot TR, Poehling KA, Hartert TV, et al. Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine. Pediatr Infect Dis J. 2004;23(8):726-731.
15. National Center for Health Statistics. National Vital Statistics System-Birth Data. http://www.cdc.gov/nchs/births.htm. Accessed August 20, 2008.
16. Black S, Shinefield H, Fireman B, et al; Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19(3):187-195.
17. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495-1502.
18. Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety, and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine. 2007;25(12):2194-2212.
19. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404-413.
20. Exact Binomial and Poisson Confidence Intervals. http://statpages.org/ confint.html. Accessed September 15, 2008.
21. Guyer B, Freedman MA, Strobino DM, Sondik EJ. Annual summary of vital statistics: trends in the health of Americans during the 20th century. Pediatrics. 2000; 105(3):E33.
22. Centers for Disease Control and Prevention (CDC). Ten great public health achievements-United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999;48(12):241-243.
23. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362(9381):355-361.
24. Scott DA, Komjathy SF, Hu BT, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2007;25(33):6164- 6166.
25. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341-1348.
26. Prymula R, Chlibek R, Splino M, et al. Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines. Vaccine. 2008;26(35):4563-4570.
27. Clarke SC. Control of pneumococcal disease - the impact of conjugate vaccines. In: European Special Populations. London, England: Touching Briefs; 2006:27-29.
28. World Health Organization. New Vaccines against Infectious Diseases: Research and Development Status, IVR, WHO, April 2005, updated February 2006. http://www.who.int/vaccine-research/documents/en/Status-Table.pdf. Accessed August 20, 2008.
29. Lacapa R, Bliss SJ, Larzelere-Hinton F, et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis. 2008;47(4):476-484.
30. Ampofo K, Bender J, Sheng X, et al. Seasonal invasive pneumococcal disease in children: role of preceding respiratory viral infection. Pediatrics. 2008;122(2):229-237.
31. Shinall MC Jr, Peters TR, Zhu Y, Chen Q, Poehling KA. Potential impact of acceleration of the pertussis vaccine primary series for infants. Pediatrics. 2008;122(5):1021-1026.
32. Pantell RH, Newman TB, Bernzweig J, et al. Management and outcomes of care of fever in early infancy. JAMA. 2004;291(10):1203-1212.
33. Bergman DA, Mayer ML, Pantell RH, Finch SA, Wasserman RC. Does clinical presentation explain practice variability in the treatment of febrile infants? Pediatrics. 2006;117(3):787-795.
34. Luginbuhl LM, Newman TB, Pantell RH, Finch SA, Wasserman RC. Office-based treatment and outcomes for febrile infants with clinically diagnosed bronchiolitis. Pediatrics. 2008;122(5):947-954.
35. Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicity and safety of heptavalent penumoccoal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J. 2002;21(3):182-186.